Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis

Syed H.E. Zaidi,1 Chi-Chung Hui,2 Alexander Y.L. Cheah,1 Xiao-Mang You,3 Mansoor Husain,3 and Marlene Rabinovitch1

1Program in Cardiovascular Research, The Hospital for Sick Children, and Departments of Pediatrics, Laboratory Medicine, and Pathobiology and Medicine.
2Program in Developmental Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, and
3Center for Cardiovascular Research, The Toronto Hospital General Division, and Department of Medicine, University of Toronto, Toronto, Ontario, Canada, MSG 1X8

Address correspondence to: Marlene Rabinovitch, Division of Cardiovascular Research, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada, MSG 1X8. Phone: (416) 813-5918; Fax: (416) 813-7480; E-mail: mr@sickkids.on.ca

Received for publication September 3, 1998, and accepted in revised form February 23, 1999.

Serine elastases degrade elastin, stimulate vascular smooth muscle cell migration and proliferation, and are associated with myocardial damage. To evaluate the impact of elastase inhibition on cardiovascular development and disease, transgenic mice were created in which the mouse preproendothelin-1 promoter was used to target elafin overexpression to the cardiovascular system. To distinguish the transgene from endogenous elafin, constructs were made incorporating a FLAG sequence; the COOH-terminus FLAG-tagged elafin construct produced a stable, functionally active gene product and was used to create transgenic mice. Consistent with endothelin expression, abundant elafin mRNA was observed in transgenic F1 embryos (embryonic day 13.5) and in adult transgenic mouse heart, trachea, aorta, kidney, lung, and skin, but not in liver, spleen, and intestine. Functional activity of the transgene was confirmed by heightened myocardial elastase inhibitory activity. No tissue abnormalities were detected by light microscopy or elastin content. However, injection of 10 plaque-forming units (PFU) of encephalomyocarditis virus resulted in death within 11 days in 10 out of 12 nontransgenic mice compared with one out of nine transgenic littermates. This reduced mortality was associated with better cardiac function and less myocardial inflammatory damage. Thus, elafin expression may confer a protective advantage in myocarditis and other inflammatory diseases.

Introduction

Elastase and elastase inhibitors likely play important roles in regulating vasculogenesis (1). Increased serine elastase activity has been documented in a number of clinical (2–4) and experimentally induced cardiovascular diseases (5–11). For example, elevated serine elastase activity has been reported in patients with myocardial infarction and unstable angina (4), peripheral and coronary artery disease (2), and abdominal aortic aneurysm (3). In experimental studies, high elastin turnover (5) is associated with increased expression of an endogenous vascular elastase in the development and progression of pulmonary hypertension (6–8, 12). Moreover, inhibition of elastase activity reduces or prevents the development of pulmonary hypertension and associated changes in the pulmonary arteries (7, 8). Elevated serine elastase activity is present in coronary arteries following experimental heart transplant (10, 11) and in the myocardium associated with cardiac rejection (11) and murine myocarditis (13). In the murine model of myocarditis, inhibition of serine elastase activity with an orally bioavailable elastase inhibitor reduced inflammation and fibrosis and preserved myocardial function (13). Following heterotopic cardiac transplant in rabbits, coronary artery neointimal formation and myocardial rejection were greatly reduced by intravenous administration of the naturally occurring serine elastase inhibitor elafin (11). Elafin has also been used to prevent myocardial damage in a rat myocardial infarct model (14).

Elafin was originally purified from human skin, bronchial secretions (15, 16), and cultured keratinocytes (17). The cDNA encodes for a 12-kDa protein that contains a signal peptide, a transglutaminase substrate domain, and the elafin inhibitory domain (17). It belongs to a complex family of genes with multiple isoforms, some of which are expressed in a tissue-specific manner (18, 19). The elafin signal peptide targets the protein to the cell membrane, where it is cleaved. The precursor is secreted and either cross-linked to other proteins via the transglutaminase domain (17, 20, 21) or cleaved by an unknown enzyme to produce the 6-kDa mature elafin inhibitory protein (17). Both the precursor and mature elafin have been shown to possess elastase inhibitory activities (16). The elafin inhibitory domain contains eight cysteines involved in intra- or intermolecular disulfide bonds, and amino acids ala24 and met25 have been shown to interact with the active site of serine elastases (22). Elafin selectively inhibits human leukocyte elastase (HLE), porcine pancreatic elastase, and proteinase 3, but not other serine proteinases such as trypsin, chymotrypsin, plasmin, and cathepsin G (23). Elafin is constitutively expressed in the skin, trachea, and blood vessels (15, 20) and appears to be induced in disease (23, 24).

An elafin-overexpressing transgenic mouse could be
useful in addressing the role of serine elastases in vascular development and in cardiovascular diseases in which serine elastase inhibition might be of value. In the present study, we created transgenic mice that overexpress human elafin under the regulation of the preproendothelin-1 promoter, thereby assuring a high level of expression in the cardiovascular system (25, 26) and other sites (27–29). Moreover, it could be anticipated that the transgene product would be expressed as early in development as embryonic day 9.5 (E9.5), when endothelin is observed (27). It could also be anticipated that expression would increase with injuries where heightened elastase activity would be expected (23), because endothelin is also upregulated in these conditions (26, 29).

To distinguish the transgene product from native elafin, we incorporated a FLAG tag. This tagged elafin was processed correctly by vascular endothelial cells and retained biological activity. The transgenic mouse showed expression of elafin in the cardiovascular system, among other organs, and functional activity was also demonstrated. The phenotype of the mice appeared normal, using microscopic and biochemical assessment of elasin content of tissues. The transgenic mice were, however, protected from the sequelae of encephalomyocarditis (EMC) virus, as evidenced by reduced mortality, decreased myocardial inflammatory damage, and improved function. Thus, this transgenic mouse model may be useful in addressing cardiovascular and other conditions in which heightened elastase activity might contribute to pathogenesis.

Methods

Addition of 5′ untranslated region to human elafin cDNA. Plasmid pDK6 (kindly provided by J.M. Sallenave, University of Edinburgh, Edinburgh, Scotland) contained an RT-PCR fragment of elafin cDNA with only six bases at the 5′-untranslated region (UTR), but a full coding region and 3′ UTR. To include the 5′ UTR, we used the DNA as a template in a PCR reaction with the following forward primers based on the published gene sequence for human elafin (30): E1 (5′-ATAAG AATGC GGCCG CAGGC CAGGC TGGAC TGAT AAGAA TTAAT GGTGT ATGCG CTTAG CTCT-3′), E2 (5′-AGATT GTGTG GGCCT TAGCT CTTAG CAAAC CACCT TCTTG ATGAG GGCAG-3′), and a reverse primer E3 (5′-ACAGC CGTAC GCCGG CTCTT TGAGT CCTGTG CCTGA-3′). E1 and E2 overlapping primers contain 67 nucleotides of the 5′ UTR of human elafin. Nof restriction sites were also introduced at the 5′ ends of E1 and E3 to facilitate cloning into the expression vectors. The PCR product was then subcloned into the Nof site of pBluescript SK (pH2Z4, Stratagene, La Jolla, Calif., USA), and the insert was sequenced using the T7, T3, and M13 reverse primers.

Addition of FLAG sequences to human elafin cDNA. Different constructs were made that contained FLAG sequences at the NH2-terminus of the signal peptide (pHZ6), COOH-terminus of elafin (pHZ7), or NH2-terminus of mature elafin (pHZ8), i.e., the sequence encoding amino acids distal to the precursor transglutaminase domain. To add FLAG to the NH2-terminus of the signal peptide, PCR was performed using pH2Z4, a plasmid that contained the full-length elafin cDNA, and forward primer E4 (5′-ATAAG AATGC GGCCG CAGGC CAGGC TGGAC TGAT AAGAA TTAAT GGTGT ATGCG CTTAG CTCT-3′), reverse primer E5 (5′-CTTGC CTTTGC ATGCT GGTAC CGGGA CTTGA-3′), and reverse primer E3; FLAG and anti-FLAG sequences are underlined. Both PCR products were then mixed and denatured, and the 3′ end of the overlap was extended using deoxyribonucleotide triphosphates (dNTPs) and Taq DNA polymerase, followed by PCR using the flanking E4 forward and E3 reverse primers. The resulting PCR product was then digested with NotI and subcloned into the pBluescript SK (pHZ6).

To add FLAG to the COOH-terminus of mature elafin, PCR was performed using pH2Z4, oligonucleotides E4, reverse primer E7 (5′-AACAG CGACG CGATG ACAAG TGAGA CGGCGT CCTT-3′), forward primer E8 (5′-CACGTT TGCTC CGTTCG TCTTT CCTAG CCTCG GGAAC GAAAG GACCC-3′), and reverse primer E3. Both PCR products were then fused by PCR and subcloned into pBluescript SK as described previously, generating pH2Z7.

FLAG was added to the NH2-terminus of mature elafin by PCR using pH2Z4 as a template and oligonucleotides E4 and reverse primer E10 (5′-TCGTT GCATC TCCTG CCTTG TAGTC CGCTT TGAC TTTGAG CACCG-3′), and E9(5′-AACAG CGACG CGATG ACAAG CGGAG CCAGT CCAAA GTCTC-3′) and reverse primer E3. Both PCR products were then fused by PCR and subcloned into pBluescript SK as described above, generating pH2Z8. Plasmid pH2Z6, pH2Z7, and pH2Z8 were sequenced, and correct insertion of FLAG was confirmed.

Generation of preproendothelin-1-directed expression vectors. Elafin cDNA containing inserts were excised from pHZ4, pHZ6, pHZ7, and pHZ8 and subcloned into the Nof restriction site of the preproendothelin expression vector pHL3 (p5.9mPET-LUC described in ref. 25 and kindly provided by Steven Hemmerick, Roche Bio-Sciences, Palo Alto, Calif., USA) after removing the luciferase insert following Nof digestion. Plasmid pH2Z5, pH2Z9, pH2Z10, and pH2Z11, respectively, contained full-length elafin and elafin with a FLAG sequence fused to the NH2-terminus of the signal peptide, the COOH-terminus of elafin, and the NH2-terminus of mature elafin.

Cell culture and transfections. Bovine pulmonary artery endothelial cells (CPEA) were obtained from American Type Culture Collection (Rockville, Maryland, USA). Fetal ovine (100-day gestation) pulmonary artery endothelial cells (LPAE) were harvested, cultured, and characterized as previously described (31). CPEA and LPAE cells were cultured in DMEM and medium 199 (Ontario Cancer Institute, Toronto, Ontario, Canada) containing 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 250 ng/ml Fungizone. Cells were transfected with calcium phosphate (32) or lipofectamine (GIBCO BRL, Burlington, Ontario, Canada) in different experiments as described in Results. Briefly, 10 μg or 3.5 μg of DNA was used with 100-nm or 35-nm culture dishes. In some transfection studies, calcium phosphate–precipitated DNA was added to the cells. After four hours, cells were glycerol shocked for 40 s and kept in serum-containing medium for 16 h. The medium was then replaced with serum-free medium. For transfection studies using lipofectamine, DNA was mixed with liposomes, and cells were transfected in serum-free medium for four hours followed by culture in 10% serum-containing medium for 16 h. Depending on the experiment, after 30 h or five days in serum-free medium, culture medium was collected and analyzed. In cells transfected with the reporter construct (pHL3), extracts were analyzed for luciferase activity (32).

Western immunoblot. Protein extracts from cell culture media were electrophoresed on polyacrylamide Tris-glycine gels and electroblotted to nitrocellulose membranes at 25 V for 1.5 hours. To block nonspecific binding, membranes were blocked overnight at 4°C in 5% nonfat dry milk in Tris-buffered saline containing 0.1% Tween-20 (TBST). Membranes were then incubated for one hour in rabbit anti-human elafin sera (1:1,500; kindly provided by J.M. Sallenave, University of Edinburgh, Edinburgh, Scotland) or M2 monoclonal anti-FLAG (10 μg/ml)
antibodies (Eastman Kodak, New Haven, Connecticut, USA) diluted in TBST. The membranes were washed in TBST and incubated with goat anti-rabbit IgG or goat anti-mouse IgG (Bio-Rad Laboratories Inc., Hercules, California, USA) peroxidase-conjugated secondary antibodies for one hour, followed by washing in TBST and detection using the enhanced chemiluminescence system (Amersham International Plc., Oakville, Ontario, Canada).

**Assay for elafin activity.** Elafin’s biological activity was assayed in serum-free cell culture medium and in hearts from transgenic mice. Hearts were harvested from mice, washed with saline, and homogenized in water. Extracts were then centrifuged at 15,000 *g* for 15 min at 4°C. The pellet was then washed three times, resuspended in water, boiled for one minute, and recentrifuged; the supernatant was then used in the assay. To ensure that comparisons reflected equal amounts of protein, protein microassays (Bio-Rad Laboratories Inc.) were carried out. Elafin’s biological activity was monitored by the inhibition of HLE. Samples were incubated with 4–8 ng of HLE (Elastin Products, Owensville, Missouri, USA) and a fluorescent peptide substrate (MCA-Leu[2,3]-AMC; Enzyme Systems Products Inc., Livermore, California, USA). DNA (1–4 ng/µl) was then used for pronuclear injection of eggs from B6/SJL mice obtained from The Jackson Laboratory (Bar Harbor, Maine, USA) and transferred into the oviducts of CD1 foster mothers. Founder mice were identified by dot blot and Southern blot hybridization using tail DNA and 32P-ribolabeled human elafin cDNA.

**Creation of transgenic mice.** Plasmid pHZ10 was digested with XhoI, and an 8.5-kb fragment containing the 5.9-kb preproendothelin promoter, COOH-terminus FLAG-tagged elafin, SV40 polyadenylation signal, and endothelin-1 intron was gel-purified using Elutip-D column (Schleicher & Schuell, Keene, New Hampshire, USA). DNA (1–4 ng/µl) was then used for pronuclear injection of eggs from B6/SJL mice obtained from The Jackson Laboratory (Bar Harbor, Maine, USA) and transferred into the oviducts of CD1 foster mothers. Founder mice were identified by dot blot and Southern blot hybridization using tail DNA and 32P-ribolabeled human elafin cDNA.

**Northern, Southern, and dot blot analyses.** Total RNA was isolated from tissues using Trizol (GIBCO BRL) according to the protocol provided by the manufacturer; it was then electrophoresed on formaldehyde agarose gels and transferred to Hybond N+ membranes (Amersham International Plc.) (32). For Southern blot analyses, restriction enzyme–digested DNA was electrophoresed on agarose gels and transferred to Hybond N+ membranes (32). For dot blotting, 5–8 µg of total genomic DNA was blotted onto Hybond N+ membranes using a dot blot apparatus (Bio-Rad Laboratories Inc.) and the method described (32). All membranes were hybridized for one hour with radiolabeled human elafin cDNA and QuikHyb solution (Stratagene, La Jolla, California, USA). Transgene copy number was estimated by comparing the intensity of the hybridization signals in transgenic mice with the known amount of plasmid DNA (0.8–8,000 pg of pHZ10).

**Immunostaining.** Embryos were fixed overnight in 4% paraformaldehyde and embedded in paraaffin. Sections were taken for histology, deparaffinized using xylene, and gradually rehydrated in ethanol. VectaStain ABC kit (Vector Laboratories, Burlington, Ontario, Canada) was used for immunoperoxidase staining according to the manufacturer’s instructions. Rabbit anti-FLAG polyclonal antibodies (Zymed Laboratories, San Francisco, California, USA) (5 µg/ml final concentration) were used for approximately 16 h at 4°C. Immune complexes were then stained by incubation in a solution containing 0.5 mg/ml solution of 3,3’-diaminobenzidine (Sigma Chemical Co., St. Louis, Missouri, USA) in 50 mM Tris buffer (pH 7.4) and 0.015% hydrogen peroxide. Sections were then counterstained with hematoxylin.

**Immunodetection of human elafin was negative in pulmonary artery endothelial cells.** Plasmids pHZ25 and pH3L, which contained the preproendothelin-directed full-length human elafin or luciferase genes, respectively (Figure 1a), were transfected into bovine (CPAE) or fetal ovine (LPAE) pulmonary artery endothelial cells (Figure 1b). Immunodetection of human elafin was negative in pulmonary artery endothelial cells transfected with the luciferase plasmid, but transfection with the plasmid containing human elafin under the regulation of the...
preproendothelin-1 promoter showed that the protein was correctly processed and secreted into the medium. Both the precursor (~10 kDa) and the processed forms of mature elafin (~6 kDa) were evident. Expression of elafin in LPAE cells was much lower when compared with the CPAE cells, as assessed by luciferase activity after cotransfection with pHZ5 (E, human elafin) constructs using calcium phosphate, and culture medium was analyzed by Western immunoblotting using anti-human elafin antisera. Migration of molecular weight markers is denoted along the left. (c) Addition of FLAG epitope to human elafin. Several constructs were generated and contained FLAG sequences at the NH2-terminus of signal peptide (pHZ9), COOH-terminus of elafin (pHZ10), and NH2-terminus of mature elafin (pHZ11). These constructs were then evaluated for FLAG-tagged elafin processing in CPAE cells, using the transfection conditions described for the pHZ5 construct. Anti-FLAG monoclonal antibody M2 was used for the Western immunoblot and demonstrated that the precursor and the processed elafin forms were detectable in culture medium of CPAE cells transfected with COOH-terminus and NH2-terminus FLAG-tagged mature elafin constructs. L, 5, 9, 10, and 11, along the top of the Western blot, represent cells transfected with pHZ5 (luciferase), pHZ9, pHZ29, pHZ10, and pHZ11, respectively. Schematic representation of processing, shown on the left, indicates signal peptide cleavage, secretion of precursor, and processing to release mature elafin.
construct pHZ10) was then evaluated for its inhibitory activity against HLE. CPAE cells transfected with plasmid pHZ5 (elafin without FLAG) or pHZ10 showed 2.4 times higher inhibitory activity than those transfected with pH3 (luciferase) (P = 0.001; Figure 2). The inhibitory activity of pHZ10-transfected cells was not significantly different from cells transfected with pHZ5. Cells transfected with pH3 exhibited endogenous inhibitory activity that could be due to elafin or other inhibitors of HLE produced by these cells.

Multiple copies of transgenes are tandemly integrated into the mouse genome. Southern blot of genomic DNA digested with BamHI from four of the five founders revealed a 4-kb BamHI fragment, as expected, suggesting that the transgene is intact and downstream of the preproendothelin-1 promoter (Figure 3a, left). Transgenic lines 2M and 14F had five to 10 copies, 3M one to two copies, and 7F 10 to 20 copies per genome. To identify the orientation of these multiple copies, genomic DNA was digested with NheI, which has two sites upstream of the elafin cDNA in the transgene (Figure 3a, right). Hybridization with elafin cDNA determines whether integration of multiple copies is tandem, reverse, or scattered (Figure 3b). Transgenic founders 14F, 2M, and 3M showed correct orientation of the transgene. In founder 7F, most copies were arranged with tandem repeats and two copies in reverse orientation. All founders except 7F showed germ-line transmission.

Tissue-specific expression of elafin in transgenic mice. To explore tissue-specific human elafin mRNA expression in transgenic mice, Northern blot analyses were performed on total RNA isolated from an F1 transgenic mouse from the 2M line (Figure 4). Abundant mRNA expression was observed in the heart, trachea, kidney, aorta, lung, and skin, while liver, spleen, brain, and intestine were negative. Human elafin mRNA was also expressed during development as seen in 13.5-day-old transgenic mouse embryos. No elafin mRNA differences were observed between male or female transgenic mice. Progeny from transgenic line 14F showed a similar profile of elafin mRNA expression. Nontransgenic mice showed no hybridization, revealing that human elafin cDNA does not cross-hybridize with the mouse endogenous elafin mRNA. Transgenic and nontransgenic embryos (E13.5), progeny from the 2M founder, were sectioned sagitally and immunostained with rabbit anti-FLAG polyclonal antibodies. Elafin protein expression was observed in the myocardium, trachea, lung, pulmonary outflow tract, aortic arch, and large blood vessels (Figure 5).

Elastase inhibitory activity is elevated in transgenic mouse hearts. Transgenic and nontransgenic littersmates from the 2M line were analyzed for the presence of elastase inhibitory activity in the heart. This is a minimum estimate and does not account for the release of the elafin released into the blood or cross-linked to extracellular matrix components. Transgenic mice showed more than onefold elevated elastase inhibitory activity compared with nontransgenic mice (Figure 6).

Tissue elastin content. Since no overt differences in morphology of tissues or in elastin were apparent by light microscopy, we confirmed that transgenic mice do not differ from nontransgenic littersmates in the elastin content.
tent of their tissues (Table 1). As a negative control, we used liver that did not express the elafin transgene.

Infection with EMC virus. Progeny from 2M and 14F exhibited similar levels of mRNA expression and tissue distribution, but because of the convenience of generating large numbers of F1 littermates, the 2M founder male was used instead of the 14F female. To test the importance of elafin overexpression in a cardiac disease model, we assessed EMC virus–induced myocardial damage, which has been well characterized in a DBA/2 strain of mice. Infection with the virus results in inflammation that reaches a maximum at 14 d, followed by fibrosis and impaired myocardial function evident at 28 d. Within 11 d of intraperitoneal injection with 10 PFU of EMC virus, 10 out of 12 nontransgenic mice had died, compared with only one out of nine transgenic littermates (Figure 7). None of the mice showed signs of encephalitis on coronal sections of postmortem brains. To confirm that mortality in transgenic mice was related to myocardial damage, we performed another experiment in which we determined whether cardiac function of transgenic and nontransgenic mice were divergent at day 7 after infec-

Figure 5
Elafin protein expression in transgenic mouse embryo. Transgenic founder 2M was cross-bred with wild-type CD1 female. Postfertilization 13.5-day-old embryos were retrieved and genotyped by dot blot hybridization of amniotic sac genomic DNA, using radiolabeled human elafin CDNA. Sagittal sections from transgenic and nontransgenic littermate embryos were stained with rabbit anti-FLAG polyclonal antibodies. All sections were counterstained with hematoxylin stain. a, c, and e are from transgenic embryos; b, d, and f are from nontransgenic embryos. Cross-sections of pulmonary artery (pa) outflow tract, aortic arch (aa), and trachea (t) are shown in a and b. c and d show ventricular myocardium. Right accessory lobe of lung (lg) and atria (at) are shown in e and f. Scale bar: 125 μm.

Figure 6
Transgenic mice hearts exhibit elevated elastase inhibitory activity. Hearts were harvested from two- to four-month-old F1 transgenic (T) and nontransgenic (N) littermates from 2M transgenic founder and CD1 wild-type female. Extracts were then used in an assay with HLE as described earlier. Bars represent mean ± SEM (n = 3 animals per group).

Figure 7
Survival after infection with EMC virus. Transgenic (n = 9) and nontransgenic (n = 12) F1 littermates were injected intraperitoneally with 10 PFU of EMC virus. Mortality was recorded until the experiment was terminated at day 11. Survival curves are generated based on these data.
tion and could account for the subsequent increase in mortality in nontransgenic mice (Table 2). Of 12 transgenic and 13 nontransgenic mice infected with 10 PFU of virus, one transgenic and one nontransgenic mouse died during the evaluation at day 7. Maximum +dp/dt values were ~1.8 times higher in the remaining elafin transgenic mice compared with nontransgenic littermates ($P < 0.02$), and values were similar to those in control uninfected mice. Both left ventricular and systemic systolic pressures were also higher in transgenic compared with nontransgenic mice ($P < 0.05$ for both). Mean arterial pressure, diastolic blood pressure, and –dp/dt values, although not statistically significantly different, showed a trend toward higher values in transgenic mice, whereas heart rates were similar and left ventricular diastolic pressure similarly elevated when compared with noninfected transgenic and nontransgenic littermates.

Hearts from infected transgenic ($n = 12$) and nontransgenic ($n = 13$) littermates were also analyzed for myocardial damage and inflammation seven days after infection with EMC virus. Both the percent of inflammation and the percent of myocardial damage were reduced by ≥50% in transgenic mice compared with the nontransgenic littermates ($P < 0.05$ for both) (Figure 8).

**Discussion**

We created transgenic mice that overexpress the serine elastase inhibitor elafin in the cardiovascular system under the regulation of the preproendothelin-1 promoter. We confirmed tandem integration of the elafin transgene, expression of elafin by immunohistochemistry and Northern blot, and functional activity attributable to increased production of elafin. The phenotype of the mice was normal, but following inoculation with EMC virus, the cardiac function was preserved and inflammation and damage to myocardium was reduced, resulting in decreased mortality.

Elafin expression in the human has been described in a variety of tissues, including lung, trachea, skin, and blood vessels (16, 20, 23). In blood vessels, moderate elafin immunostaining was reported in smooth muscle cells (20). To our knowledge, ours is the first report of elafin expression in pulmonary artery endothelial cells. Previous studies have not shown elafin expression in kidney, brain, liver, or heart. Preproendothelin-1 has been more extensively studied and documented in vascular endothelial cells, as well as smooth muscle cells, heart, lung, kidney, brain, and skin (27–29). Increased endothelin expression has been reported in pulmonary hyper-

---

**Figure 8**

Analysis of myocardial inflammation and damage after infection with EMC virus. Hearts from EMC-infected transgenic or nontransgenic littermates were harvested and analyzed as described in Methods. Representative photomicrographs of the myocardium are shown. (a) Nontransgenic infected mice showing a large focus of inflammation and myocyte loss. (b) Transgenic infected mice showing milder inflammation and damage. (c) Nontransgenic noninfected control mice. (d) Transgenic noninfected control mice. Insets show higher magnification of the myocardium. Scale bars: 25 μm (insets) and 200 μm. Quantification of inflammation and damaged area of the infected myocardium (mean ± SEM) is shown in e and f ($n = 12$ for transgenic mice; $n = 13$ for nontransgenic littermates).
Table 1
Elastin contents in various tissues of transgenic and nontransgenic mice

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Transgenic</th>
<th>Nontransgenic</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart</td>
<td>0.476 ± .04</td>
<td>0.492 ± .025</td>
<td></td>
</tr>
<tr>
<td>Aorta</td>
<td>10.345 ± .992</td>
<td>12.746 ± .357</td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>2.645 ± 0.218</td>
<td>2.662 ± 0.154</td>
<td></td>
</tr>
<tr>
<td>Trachea</td>
<td>3.122 ± 0.287</td>
<td>3.272 ± 0.24</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>7.125 ± 1.446</td>
<td>6.916 ± 1.313</td>
<td></td>
</tr>
</tbody>
</table>

All values are expressed as milligram of elastin per 100 milligrams of wet tissue weight, except lung and liver, where values were normalized to dry weight. Transgenic and nontransgenic four-month-old female littermates (n = 5 in each group) were used for this study. All samples were analyzed in triplicate.

Table 2
Analysis of cardiac function in mice subjected to EMC virus infection

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Transgenic</th>
<th>Nontransgenic</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>t dp/dt (ms)</td>
<td>4.472 ± 0.533*</td>
<td>2.519 ± 0.544</td>
<td>0.018</td>
</tr>
<tr>
<td></td>
<td>(4.493 ± 0.619)</td>
<td>(4.450 ± 0.815)</td>
<td>(0.970)</td>
</tr>
<tr>
<td>–dp/dt (ms)</td>
<td>3.326 ± 0.333</td>
<td>2.424 ± 0.553</td>
<td>0.233</td>
</tr>
<tr>
<td></td>
<td>(4.363 ± 2.51)</td>
<td>(3.615 ± 2.725)</td>
<td>(0.562)</td>
</tr>
<tr>
<td>LVSP (mmHg)</td>
<td>101 ± 4.24</td>
<td>73.2 ± 7.6</td>
<td>0.006</td>
</tr>
<tr>
<td></td>
<td>(110 ± 4.4)</td>
<td>(104 ± 7.5)</td>
<td>(0.537)</td>
</tr>
<tr>
<td>LVEDP (mmHg)</td>
<td>19.5 ± 4.1</td>
<td>20.8 ± 2.8</td>
<td>0.795</td>
</tr>
<tr>
<td></td>
<td>(5.3 ± 4.4)</td>
<td>(9.7 ± 3.4)</td>
<td>(0.455)</td>
</tr>
<tr>
<td>HR (beats per minute)</td>
<td>270 ± 24</td>
<td>296 ± 20</td>
<td>0.413</td>
</tr>
<tr>
<td></td>
<td>(262 ± 56)</td>
<td>(267 ± 21)</td>
<td>(0.930)</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>110 ± 6.3*</td>
<td>87 ± 7.9</td>
<td>0.036</td>
</tr>
<tr>
<td></td>
<td>(131 ± 8.7)</td>
<td>(128 ± 11)</td>
<td>(0.881)</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>80.3 ± 4.9</td>
<td>65.7 ± 6.4</td>
<td>0.090</td>
</tr>
<tr>
<td></td>
<td>(81 ± 8.6)</td>
<td>(83 ± 3.5)</td>
<td>(0.769)</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>90.2 ± 5.2</td>
<td>72.9 ± 6.9</td>
<td>0.062</td>
</tr>
<tr>
<td></td>
<td>(97.7 ± 8.3)</td>
<td>(98.3 ± 5.8)</td>
<td>(0.949)</td>
</tr>
</tbody>
</table>

Data from control noninfected mice are shown in parentheses. *Significantly different.

Different strains of mice are differentially susceptible to EMC virus (unpublished data from our laboratory), and the genetic background of the animals used in this study (B6/SJL/CD1) resulted in a much more severe form of EMC virus–induced myocarditis than previously reported in DBA/2 mice (13, 35). This more severe form of myocarditis allowed us to show a substantial impact of elafin transgene expression on EMC virus–induced mortality. This impact suggested that serine elastases were not only important in the development of fibrosis, as deduced from our previous work, but were also involved in the initial response of the organism to viral toxicity. Serine elastase inhibitors do not affect EMC virus propagation (13, 40). Rather, the protective effect was associated with preserved cardiac function at a time in the evolution of the disease where there is only an early influx of inflammatory cells. There was a significant difference in +dp/dt in transgenic compared with nontransgenic mice, suggesting that cardiac function was preserved. We confirmed reduced inflammation and associated myocardial tissue damage.

Since elafin expression has been documented in the vessel wall, agents that increase its level may provide protection against cardiovascular diseases where serine elastases are important. It is possible that endogenous expression of elafin might be a genetic background fac-
tor that influences susceptibility to disease and explains, for example, why patients infected with the same myocarditis-causing virus can have major differences in initial presentation and recovery.

Acknowledgments

The authors wish to thank the transgenic facility at the Hospital for Sick Children; Claire Coulber, Sorana Ciura, and Eva Sitarz for technical assistance; and Joan Jowlabar, Judy Edwards, and Judy Matthews for secretarial assistance. This study was supported by Heart and Stroke Foundation of Canada grant HSFO 2649. M. Rabinovitch is a chair of the Heart and Stroke Foundation of Canada, and M. Husain is a Clinician Scientist of the Medical Research Council of Canada.